<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04726631</url>
  </required_header>
  <id_info>
    <org_study_id>IS-PREG</org_study_id>
    <nct_id>NCT04726631</nct_id>
  </id_info>
  <brief_title>Insulin in Treatment of Diabetes Mellitus With Pregnancy</brief_title>
  <official_title>Insulin Analogue Versus Conventional Premixed Insulin in the Treatment of Diabetes Mellitus With Pregnancy: A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of diabetes melilites is rapidly increasing over years and consequently during&#xD;
      pregnancy. In 2017, there were 21.3 million pregnant women who experienced hyperglycemia, of&#xD;
      which 86.4% of them were diagnosed with gestational diabetes melilites.&#xD;
&#xD;
      Pregnancy in women with diabetes is associated with an intensification in adverse maternal,&#xD;
      fetal and perinatal outcomes including spontaneous abortions, congenital malformations,&#xD;
      preterm labor, and macrosomia. Several studies have confirmed that poor glycemic control in&#xD;
      women with either gestational, type 1 or type 2 diabetes during pregnancy is associated with&#xD;
      poor pregnancy outcomes. In the same line, proper glycemic control before, early, and through&#xD;
      all pregnancy markedly improves both maternal and fetal outcomes.&#xD;
&#xD;
      Insulin therapy is the standard treatment of diabetes melilites with the pregnancy if dietary&#xD;
      control and exercise fail. However, insulin therapy has its difficulties like approaches to&#xD;
      mimicking postprandial insulin release, providing adequate background insulin, balancing&#xD;
      insulin dosage, food, activity, hypoglycemic episodes, overall glycemia. This is always a&#xD;
      struggle for doctors and patients and much affecting their lifestyle&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2015</start_date>
  <completion_date type="Actual">December 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 1, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage of maternal glycosylated Hemoglobin</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Basal insulin analogue and premeal rapid acting insulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neutral Protamine Hagedorn with regular insulin</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basal insulin analogue</intervention_name>
    <description>Analogue insulin is a sub-group of human insulin</description>
    <arm_group_label>Basal insulin analogue and premeal rapid acting insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rapid acting insulin</intervention_name>
    <description>Rapid acting insulins are usually taken just before or with a meal. They act very quickly to minimise the rise in blood sugar which follows eating.</description>
    <arm_group_label>Basal insulin analogue and premeal rapid acting insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neutral Protamine Hagedorn</intervention_name>
    <description>is an intermediate-acting insulin</description>
    <arm_group_label>Neutral Protamine Hagedorn with regular insulin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>regular insulin</intervention_name>
    <description>is a type of short-acting insulin.</description>
    <arm_group_label>Neutral Protamine Hagedorn with regular insulin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age of 18 - 45 years old,&#xD;
&#xD;
          -  Women with pre-gestational diabetes.&#xD;
&#xD;
          -  Those who were under premixed insulin therapy prior to pregnancy.&#xD;
&#xD;
          -  women pregnant between 14 weeks up to 28 weeks of gestation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of recurrent miscarriage&#xD;
&#xD;
          -  multiple pregnancies&#xD;
&#xD;
          -  chronic hypertension&#xD;
&#xD;
          -  severe heart, liver, and kidney disease.&#xD;
&#xD;
          -  women how got pregnant after assisted reproduction&#xD;
&#xD;
          -  those with advanced retinopathy, hypersensitivity to insulin.&#xD;
&#xD;
          -  Women who developed bleeding in early pregnancy and those diagnosed to have any major&#xD;
             anomaly during the first-trimester scan.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 23, 2021</study_first_submitted>
  <study_first_submitted_qc>January 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>January 23, 2021</last_update_submitted>
  <last_update_submitted_qc>January 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin, Short-Acting</mesh_term>
    <mesh_term>Protamines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

